Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825141 | 0.78 | HTR6 (0.45) | CPT1APRPS1CNR2CNR1MCL1 | |
| SCHEMBL2642993 | 0.76 | CNR2 (0.48) | CPT1APRPS1CNR2CNR1MCL1 | |
| SCHEMBL12480220 | 0.74 | PTGDR2 (0.44) | CNR2CNR1ALDH1A1MAPTKMT2A | |
| SCHEMBL828230 | 0.74 | MTNR1A (0.46) | PRPS1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2642659 | 0.74 | CNR2 (0.51) | PRPS1CNR2CNR1ALDH1A1 | |
| SCHEMBL2642676 | 0.73 | KDM4E (0.48) | CPT1ACNR2CNR1ALDH1A1MEN1 | |
| SCHEMBL3098967 | 0.73 | HTR6 (0.59) | CPT1APRPS1CNR2CNR1MCL1 | |
| SCHEMBL2643935 | 0.73 | PTGDR2 (0.43) | CPT1APRPS1CNR2CNR1MCL1 | |
| SCHEMBL2643380 | 0.73 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL27764118 | 0.71 | CPT1A (0.38) | CPT1APRPS1CNR2CNR1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2125785-B1 | INDOLE-3-YL-CARBONYL-PIPERIDINE- DERIVATIVES FOR THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS VIA V1A RECEPTOR ANTAGONISM | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011132443-A1 | SURFACE ACOUSTIC WAVE DEVICE AND MANUFACTURING METHOD OF SAME | 株式会社村田製作所 (JP) | 2011-10-27 | — | — | WO | disclosed |
| EP-2125785-A1 | INDOLES | F. Hoffmann-Roche AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| CN-101583609-A | Indoles | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | CN | disclosed |
| WO-2008080842-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080167344-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161315-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | CPT1A 1563/4885PRPS1 3839/4885CDK2 468/4885 |
| US-20080167344-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | CPT1A 1563/4885PRPS1 3839/4885CDK2 468/4885 |
| US-20080161316-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | CPT1A 1563/4885PRPS1 3839/4885CDK2 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.